Clinical Trials
95 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
National Institutes of Health Clinical Center (CC)
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma, Inc.
Study of Continuous OSI-906 Dosing
Astellas Pharma Inc
Study of Intermittent OSI-906 Dosing
Astellas Pharma Inc
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Case Comprehensive Cancer Center
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Ludwig Institute for Cancer Research
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Ludwig Institute for Cancer Research
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Immunotherapy Study for Metastatic Renal Cell Cancer
Lumos Pharma
JAVELIN Renal 100
Pfizer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Corvus Pharmaceuticals, Inc.
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
Jonsson Comprehensive Cancer Center
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
National Institutes of Health Clinical Center (CC)
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
Cancer Targeted Technology
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
National Institutes of Health Clinical Center (CC)
Vaccine Therapy in Treating Patients With Kidney Cancer
Memorial Sloan Kettering Cancer Center
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Medical University of South Carolina
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
AMG 172 First in Human Study in Patients With Kidney Cancer
Amgen
PTK/RAD
Duke University
Percutaneous Renal Tumor Cryoablation Followed by Biopsy
Memorial Sloan Kettering Cancer Center